Online citations, reference lists, and bibliographies.
← Back to Search

Cannabidiol As A Potential Treatment For Anxiety Disorders

E. Blessing, M. Steenkamp, J. Manzanares, C. Marmar
Published 2015 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.
This paper references
10.3171/JNS.1969.30.1.0014
Sensations evoked by stimulation in the midbrain of man.
B. Nashold (1969)
10.1016/0014-2999(74)90129-0
Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.
I. G. Karniol (1974)
Comparative effects between cannabidiol and diazepam on neophobia food intake and conflict behavior
N. G. S. Filho (1981)
Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol.
A. W. Zuardi (1981)
Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.
A. Zuardi (1982)
10.1002/SYN.890010103
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
J. Sprouse (1987)
Pharmacological characterization of cannabinoids in the elevated plus maze.
E. Onaivi (1990)
Antianxiety e f f ec t o f cannab id io l in the e l eva ted p lu s -maze
FS Guimaraes (1990)
10.1177/026988119300700112
Effects of ipsapirone and cannabidiol on human experimental anxiety
A.W. Zuardi (1993)
10.1016/0166-2236(94)90047-7
Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?
R. Bandler (1994)
10.1038/sj.bjp.0704327
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Tiziana Bisogno (2001)
10.1016/S0149-7634(01)00060-4
Modeling panic attacks
L. Schenberg (2001)
10.1006/nimg.2000.0685
Mapping Motor Inhibition: Conjunctive Brain Activations across Different Versions of Go/No-Go and Stop Tasks
K. Rubia (2001)
10.1176/APPI.AJP.158.12.1989
An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.
M. Otto (2001)
10.1016/S0165-6147(00)01712-0
Anandamide: some like it hot.
V. Di Marzo (2001)
Mappingmotor inhibition: conjunctive brain activations across different versions of go/no-go and stop
K Rubia (2001)
10.1016/S0165-0327(01)00354-8
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.
A. Khan (2002)
10.1038/nature00839
The endogenous cannabinoid system controls extinction of aversive memories
G. Marsicano (2002)
10.1126/SCIENCE.1063545
Endocannabinoid Signaling in the Brain
R. Wilson (2002)
10.1523/JNEUROSCI.5491-03.2004
Memory Reconsolidation and Extinction Have Distinct Temporal and Biochemical Signatures
A. Suzuki (2004)
10.1038/sj.npp.1300340
Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow
J. Crippa (2004)
10.4088/JCP.V65N1216
Remission rates in patients with anxiety disorders treated with paroxetine.
J. Ballenger (2004)
10.1016/j.pbb.2005.01.029
Endocannabinoid system and stress and anxiety responses
M. Viveros (2005)
10.1007/s11064-005-6978-1
Agonistic Properties of Cannabidiol at 5-HT1a Receptors
E. B. Russo (2005)
10.1001/ARCHPSYC.62.6.593
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
R. Kessler (2005)
10.1007/BF02244012
Antianxiety effect of cannabidiol in the elevated plus-maze
F. Guimarães (2005)
10.1038/sj.npp.1300601
Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable Stress
M. Hill (2005)
10.1111/j.1468-1331.2005.01202.x
Cost of disorders of the brain in Europe
P. Andlin-Sobocki (2005)
10.1001/ARCHPSYC.62.6.629
Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.
P. Wang (2005)
10.1016/j.pnpbp.2006.06.004
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
F. Moreira (2006)
10.1002/14651858.CD006115
Azapirones for generalized anxiety disorder.
C. Chessick (2006)
10.1016/j.bbr.2006.05.016
Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
L. Resstel (2006)
10.1002/CBDV.200790147
Cannabidiol – Recent Advances
R. Mechoulam (2007)
10.1016/J.CPR.2007.01.015
Quality of life in the anxiety disorders: a meta-analytic review.
B. Olatunji (2007)
10.7326/0003-4819-146-5-200703060-00004
Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, and Detection
K. Kroenke (2007)
Cannabidiol—recent advances. Chem Biodivers 2007;4:16781692
R Mechoulam (2007)
10.1007/s00213-008-1168-x
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
A. Campos (2008)
10.1093/CERCOR/BHM161
Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex.
T. Rubino (2008)
10.1192/bjp.bp.107.046649
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
C. Morgan (2008)
10.1111/j.1369-1600.2008.00104.x
The endocannabinoid system: emotion, learning and addiction
F. Moreira (2008)
10.1016/j.biopsych.2008.05.011
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
S. Borgwardt (2008)
10.1016/j.euroneuro.2008.07.001
Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats
R. M. Bitencourt (2008)
10.1007/s00213-009-1494-7
Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats
J. Haller (2009)
10.1007/s00213-009-1466-y
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety
Alexia M. Thomas (2009)
10.1016/j.pnpbp.2009.08.017
Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids
A. Campos (2009)
10.1016/j.tips.2009.07.006
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
A. Izzo (2009)
10.1001/archgenpsychiatry.2008.519
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
P. Fusar-Poli (2009)
10.1016/j.pnpbp.2009.06.022
Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses
D. Walker (2009)
10.1111/j.1476-5381.2008.00046.x
5‐HT1A receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
L. Resstel (2009)
10.1016/j.tins.2008.12.006
Hot flash: TRPV channels in the brain
J. Kauer (2009)
Facilitation of contextual fear memory extinction and anti-anxiogenic effects of A M
Rm Bitencourt (2009)
10.1210/en.2010-0285
Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling.
N. Evanson (2010)
10.1038/npp.2010.58
Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
C. Morgan (2010)
10.1192/bjp.bp.110.077503
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study
C. Morgan (2010)
10.1017/S1461145709990617
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.
P. Fusar-Poli (2010)
10.1016/j.bbr.2009.09.045
Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats
J. I. Lemos (2010)
10.1038/npp.2009.184
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
S. Bhattacharyya (2010)
10.1016/j.bbr.2010.05.004
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
V. Soares (2010)
10.1097/FBP.0b013e32833b33c5
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
P. Casarotto (2010)
10.1017/S1461145709990605
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
L. Long (2010)
10.1007/s00213-010-2036-z
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
F. Gomes (2010)
Modulation of effective connectivity during emotional processing by Delta 9t e t r a h y d r o c a n n a b i n o l a n d c a n n a b i d i o l
P Fusar-Poli (2010)
10.2174/157488611798280924
Safety and side effects of cannabidiol, a Cannabis sativa constituent.
M. Bergamaschi (2011)
10.1001/jama.2011.1080
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
J. Krystal (2011)
10.1038/npp.2011.6
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
M. Bergamaschi (2011)
10.1177/0269881110379283
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
J. Crippa (2011)
10.1007/s00213-011-2566-z
Anxiogenic-like effects of chronic cannabidiol administration in rats
Maha M. ElBatsh (2011)
10.3389/fnbeh.2011.00063
Endocannabinoid System and Psychiatry: In Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects
E. M. Marco (2011)
10.1016/j.pbb.2011.06.027
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress
É. M. Granjeiro (2011)
10.1007/s00213-011-2415-0
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour
S. Deiana (2011)
10.1038/npp.2010.184
Dissociable Roles of Prelimbic and Infralimbic Cortices, Ventral Hippocampus, and Basolateral Amygdala in the Expression and Extinction of Conditioned Fear
Demetrio Sierra-Mercado (2011)
10.1016/j.euroneuro.2011.08.008
Cost of disorders of the brain in Europe 2010
A. Gustavsson (2011)
10.1016/j.drugalcdep.2010.09.020
Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol.
T. Demirakca (2011)
Cannabidiol reduces the anxiety induced by simulated public speaking in t r e a t m e n t - n a i v e s o c i a l p h o b i a p a t i e n t s
MM Bergamaschi (2011)
10.1002/dta.1377
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
T. Passie (2012)
10.1016/j.neuron.2012.09.020
Endocannabinoid Signaling and Synaptic Function
P. E. Castillo (2012)
10.1177/0269881110389095
Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors
F. Gomes (2012)
10.3389/fnbeh.2012.00009
The endocannabinoid system: an overview
N. Battista (2012)
10.1177/0269881111408958
The endocannabinoid system in anxiety, fear memory and habituation
S. Ruehle (2012)
10.1007/s00213-012-2878-7
Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats
A. Campos (2012)
10.1016/j.jpsychires.2012.08.012
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.
A. Campos (2012)
10.1038/npp.2011.188
Anti-Aversive Effects of Cannabidiol on Innate Fear-Induced Behaviors Evoked by an Ethological Model of Panic Attacks Based on a Prey vs the Wild Snake Epicrates cenchria crassus Confrontation Paradigm
A. Uribe-Mariño (2012)
10.1038/npp.2012.63
On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment
C. A. Stern (2012)
10.1016/j.neuropharm.2011.08.013
Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats
Y. Hsiao (2012)
10.2174/138161212802884780
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
R. Martín-Santos (2012)
10.1007/s00213-012-2955-y
Cannabidiol enhances consolidation of explicit fear extinction in humans
R. Das (2012)
10.1016/j.neuroscience.2011.11.057
Fear relief—toward a new conceptual frame work and what endocannabinoids gotta do with it
C. J. Riebe (2012)
10.1016/j.neubiorev.2012.06.003
Neurocircuitry models of posttraumatic stress disorder and beyond: A meta-analysis of functional neuroimaging studies
R. Patel (2012)
10.1111/j.1476-5381.2011.01621.x
Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
EM Rock (2012)
10.1016/j.neuroscience.2011.08.046
Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety—two sides of one coin?
F. Moreira (2012)
10.1590/S1516-44462012000500008
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Alexandre Rafael de Mello Schier (2012)
10.1098/rstb.2011.0389
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
A. Campos (2012)
Fear relieftoward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 2012;204:159-185
CJ Riebe (2012)
10.4088/JCP.12m08020
Inhibitory neural activity predicts response to cognitive-behavioral therapy for posttraumatic stress disorder.
E. Falconer (2013)
10.1177/0269881113493363
The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae)
A. Twardowschy (2013)
10.1016/j.pharmthera.2012.12.002
Endocannabinoid system and mood disorders: priming a target for new therapies.
V. Micale (2013)
10.1016/j.euroneuro.2012.09.007
Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT1A receptor
F. Gomes (2013)
10.1017/S1461145712001502
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
A. Campos (2013)
10.1016/j.cmet.2013.03.001
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders.
C. Silvestri (2013)
10.1002/syn.21621
Facilitation of fear extinction by the 5‐HT1A receptor agonist tandospirone: Possible involvement of dopaminergic modulation
Yasuhiro Saito (2013)
10.1177/0269881113485144
Cooperative regulation of anxiety and panic-related defensive behaviors in the rat periaqueductal grey matter by 5-HT1A and µ-receptors
C. M. Roncon (2013)
10.1007/s40263-013-0071-0
Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
P. Celada (2013)
10.1016/j.pnpbp.2012.10.024
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
V. Almeida (2013)
10.1016/j.bbr.2013.04.045
Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors
F. D. Monte (2013)
10.1038/npp.2013.51
Cannabinoids Ameliorate Impairments Induced by Chronic Stress to Synaptic Plasticity and Short-Term Memory
H. Abush (2013)
10.1002/da.22031
THE ENDOCANNABINOID SYSTEM PROVIDES AN AVENUE FOR EVIDENCE‐BASED TREATMENT DEVELOPMENT FOR PTSD
A. Neumeister (2013)
10.3389/fpsyt.2013.00130
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
R. Niesink (2013)
10.1007/s00213-013-3350-z
Activation of postsynaptic 5-HT1A receptors improve stress adaptation
Jiansong Zhou (2013)
Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation. Synapse 2013;67:161-170
Y Saito (2013)
10.1016/j.neubiorev.2014.02.006
A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior
R. McLaughlin (2014)
10.2174/13816128113199990427
Cannabinoids and schizophrenia: therapeutic prospects.
P. Robson (2014)
10.1016/j.euroneuro.2013.10.012
Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience
M. Fogaça (2014)
10.1016/j.neubiorev.2014.03.026
Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channels
D. Aguiar (2014)
10.1016/j.jad.2014.06.041
A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis.
M. Mochcovitch (2014)
10.1080/02791072.2013.873843
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
G. Greer (2014)
10.1176/appi.ps.201300234
Associations of psychotherapy dose and SSRI or SNRI refills with mental health outcomes among veterans with PTSD.
Hana J. Shin (2014)
10.1111/fcp.12051
Cannabidiol reverses the mCPP‐induced increase in marble‐burying behavior
M. Nardo (2014)
10.1111/epi.12631
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
O. Devinsky (2014)
10.2174/1871527313666140612114838
Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.
Alexandre R de Mello Schier (2014)
10.1523/JNEUROSCI.4112-14.2015
Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release
S. Lee (2015)
10.1016/j.ejphar.2015.03.051
Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon.
Juliana Almeida da Silva (2015)
10.1016/j.neuropharm.2015.03.007
Activation of 5-HT1A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease
Yi-Na Sun (2015)
10.1523/JNEUROSCI.2737-14.2015
Corticotropin-Releasing Hormone Drives Anandamide Hydrolysis in the Amygdala to Promote Anxiety
J. M. Gray (2015)
10.1016/j.euroneuro.2014.11.014
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users
C. Hindocha (2015)
10.1016/j.neuron.2015.02.015
Chronic Stress Induces Anxiety via an Amygdalar Intracellular Cascade that Impairs Endocannabinoid Signaling
Z. Qin (2015)
10.1517/13543784.2015.1020109
Investigational drugs under development for the treatment of PTSD
B. Ragen (2015)
10.1038/ncomms7395
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Iva Dincheva (2015)
10.1007/s00213-015-3917-y
2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons
Á. Llorente-Berzal (2015)
10.1111/bph.12944
Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
J. Mcpartland (2015)
10.1016/j.biopsycho.2014.10.010
Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research
Santiago Papini (2015)



This paper is referenced by
10.1055/A-1301-3135
Endocannabinoidsystem und Stress
J. Spohrs (2021)
10.36118/PHARMADVANCES.2021.04
Cannabidiol and the central nervous system: translating into clinics
Anella Saviano (2021)
10.1186/s42238-021-00069-x
What are the informational pathways that shape people’s use of cannabidiol for medical purposes?
M. Zenone (2021)
10.1371/journal.pone.0245471
Cannabis sativa subsp. sativa’s pharmacological properties and health effects: A scoping review of current evidence
Xin Yi Lim (2021)
10.3389/fpsyg.2021.687106
Impact of Acute and Chronic Cannabis Use on Stress Response Regulation: Challenging the Belief That Cannabis Is an Effective Method for Coping
M. al'Absi (2021)
10.3389/fphar.2021.626010
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
F. Navarrete (2021)
10.1007/s00213-021-05823-w
Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study
Toni C Spinella (2021)
10.1038/s41398-020-01177-7
Fear extinction learning and anandamide: an fMRI study in healthy humans
Jennifer Spohrs (2021)
10.3390/ijms22020730
Do Adolescent Exposure to Cannabinoids and Early Adverse Experience Interact to Increase the Risk of Psychiatric Disorders: Evidence from Rodent Models
Anna Portugalov (2021)
10.1016/J.INDCROP.2021.113433
Wavelengths of LED light affect the growth and cannabidiol content in Cannabis sativa L
Xiuye Wei (2021)
10.3389/fpsyt.2021.638032
From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?
R. M. Bitencourt (2021)
10.3389/fpsyt.2021.597725
Cannabis Use and Mental Illness: Understanding Circuit Dysfunction Through Preclinical Models
Bryan W. Jenkins (2021)
10.3390/ph14050462
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy
Alice Palermiti (2021)
10.3390/biomedicines9030234
Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
Jackson M J Oultram (2021)
10.1038/s41380-021-01086-1
Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway
A. Vallée (2021)
10.1080/15440478.2021.1907834
Industrial Hemp—an Old but Versatile Bast Fiber Crop
Xinlin Zhao (2021)
10.1021/ACS.CHAS.0C00119
Fall 2020 Proceedings of the Cannabis Chemistry Subdivision
N. Arora (2021)
10.3389/fphar.2021.694510
Cannabidiol and Sertraline Regulate Behavioral and Brain Gene Expression Alterations in an Animal Model of PTSD
A. Gasparyan (2021)
10.1371/journal.pone.0251677
Studies of involvement of G-protein coupled receptor-3 in cannabidiol effects on inflammatory responses of mouse primary astrocytes and microglia
Jun Wu (2021)
10.1177/0269881120965952
Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice
C. Calpe-López (2021)
10.3390/ijms22094876
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
R. Vitale (2021)
10.3390/ijerph18136719
Availability and Promotion of Cannabidiol (CBD) Products in Online Vape Shops
E. Leas (2021)
10.1186/s12954-021-00520-5
Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample
Sinikka L. Kvamme (2021)
10.3389/fpsyt.2021.620073
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Michał Graczyk (2021)
Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220).
K. Blum (2021)
10.1017/9781108650182.024
Pharmaceuticals and Alternatives for Wellness
Thomas Parisi (2020)
10.1016/j.bbrc.2020.10.021
Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids.
Sarah H. Shrader (2020)
10.1111/bcp.14399
A pilot randomised placebo‐controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability
D. Efron (2020)
10.1017/9781108650182.041
Developing Purpose, Meaning, and Achievements
J. Vilhauer (2020)
10.1017/9781108650182.014
Wellness Interventions in Patients Living with Chronic Medical Conditions
A. J. Steiner (2020)
10.1590/1516-4446-2020-1416
Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study.
C. Meneses-Gaya (2020)
10.1017/9781108650182.027
Sex, Intimacy, and Well-Being
Kailee Marin (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar